• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arch Pathol Lab Med . Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Qualitative IgG Assays: The Value of Numeric Reporting

tetano

Editor, Senior Moderator
Arch Pathol Lab Med


. 2021 Apr 5.
doi: 10.5858/arpa.2020-0851-SA. Online ahead of print.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Qualitative IgG Assays: The Value of Numeric Reporting


Stefanie K Forest[SUP] 1 [/SUP], Erika P Orner[SUP] 1 [/SUP], D Yitzchak Goldstein[SUP] 1 [/SUP], Ariel S Wirchnianski[SUP] 1 [/SUP], Robert H Bortz[SUP] 1 [/SUP], Ethan Laudermilch[SUP] 1 [/SUP], Catalina Florez[SUP] 1 [/SUP], Ryan J Malonis[SUP] 1 [/SUP], George I Georgiev[SUP] 1 [/SUP], Olivia Vergnolle[SUP] 1 [/SUP], Yungtai Lo[SUP] 1 [/SUP], Sean T Campbell[SUP] 1 [/SUP], Jason Barnhill[SUP] 1 [/SUP], Evan M Cadoff[SUP] 1 [/SUP], Jonathan R Lai[SUP] 1 [/SUP], Kartik Chandran[SUP] 1 [/SUP], Louis M Weiss[SUP] 1 [/SUP], Amy S Fox[SUP] 1 [/SUP], Michael B Prystowsky[SUP] 1 [/SUP], Lucia R Wolgast[SUP] 1 [/SUP]



Affiliations

Abstract

Context: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG testing is used for serosurveillance and will be important to evaluate vaccination status. Given the urgency to release coronavirus disease 2019 (COVID-19) serology tests, most manufacturers have developed qualitative tests.
Objective: To evaluate clinical performance of six different SARS-CoV-2 IgG assays and their quantitative results to better elucidate the clinical role of serology testing in COVID-19.
Design: Six SARS-CoV-2 IgG assays were tested using remnant specimens from 190 patients. Sensitivity and specificity were evaluated for each assay with the current manufacturer's cutoff and a lower cutoff. A numeric result analysis and discrepancy analysis were performed Results: The specificity was >93% for all assays, and sensitivity was >80% for all assays (? 7 days post-polymerase chain reaction [PCR] testing). Inpatients with more severe disease had higher numeric values compared to health care workers with mild or moderate disease. Several discrepant serology results were those just below the manufacturers cutoff.
Conclusions: SARS-CoV-2 IgG antibody testing can aid in the diagnosis of COVID-19 especially with negative PCR. Quantitative COVID-19 IgG results are important to better understand the immunological response and disease course of this novel virus and to assess immunity as part of future vaccination programs.
 
Back
Top Bottom